People with alcohol addiction lack key enzyme: Scientists

Image
IANS London
Last Updated : Aug 30 2016 | 4:32 PM IST

In people with alcohol dependence, the production of a key enzyme shuts down in brain cells and the deficiency leads to continued use of alcohol despite adverse consequences, say researchers.

The enzyme, PRDM2, has previously been studied in cancer research.

"But we didn't know that it has a function in the brain," said Markus Heilig, head of the Centre for Social and Affective Neuroscience (CSAN) at Linköping University in Sweden.

It has long been suspected that people with alcohol dependence have impaired function in the frontal lobes of the brain but the underlying biological mechanisms have not been known.

The research team, which includes researchers from both Linköping University and University of Miami, is the first to identify this molecular mechanism.

If frontal function is impaired, it is difficult for us to control our impulses.

A person with intact impulse control can walk past a bar on a warm day and think "a beer would be nice, but I can't have one now because I have to get back to work".

An alcoholic does not have sufficient impulse control to refrain, thinking: "It's hot and I'm thirsty".

"PRDM2 controls the expression of several genes that are necessary for effective signalling between nerve cells. When too little enzyme is produced, no effective signals are sent from the cells that are supposed to stop the impulse," Professor Heilig noted.

The team has shown that alcohol dependence in rats leads to a down-regulation of PRDM2 production, which, in turn, leads to disruption of impulse control.

When the researchers knocked out the production of PRDM2 in the frontal lobes of rats that were not dependent, they observed the same behaviour - impulse control was disrupted.

"Over the long term, we want to contribute to developing effective medicines, but over the short term the important thing is to do away with the stigmatisation of alcoholism," Professor Heilig added.

The discovery was published in the journal Molecular Psychiatry.

--IANS

na/bg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 30 2016 | 4:22 PM IST

Next Story